红细胞分布宽度与STAT3表达在弥漫性大B细胞淋巴瘤预后评估中的临床意义

Clinical significance ofred blood cell distribution width and STAT3 expression score in prognosis assessment of diffuse large B cell lymphoma

目的探讨弥漫性大B细胞淋巴瘤患者治疗前红细胞分布宽度(RDW)、STAT3表达与预后的关系及其临床意义。方法收集2015年1月至2018年12月间98例诊断为弥漫性大B细胞淋巴瘤(DLBCL)患者的基线资料。分析RDW、STAT3与DLBCL临床病理特征(Ann Arbor分期、Hans标准分型、乳酸脱氢酶和ECOG-PS)的关系,探讨RDW、STAT3与DLBCL预后的关系。结果ROC曲线结果显示,RDW和STAT3的cut-off值分别为14.55%和23.85%,根据cut-off值将DLBCL患者分为高低RDW组和高低STAT3表达组。RDW、STAT3与性别、年龄与ECOG PS评分均无关(P>0.05),与LDH水平、Hans分型和Ann Arbor分期有关,差异有统计学意义(P<0.05)。高RDW组和高STAT3组患者总生存期显著低于低RDW组和低STAT3表达患者(P<0.05)。结论红细胞分度宽度与STAT3表达可以作为评估弥漫性大B细胞淋巴瘤患者临床病理特征及预后的便捷指标。

Objective To investigate the relationship between red blood cell distribution width(RDW),STAT3 expression and prognosis of patients with diffuse large B-cell lymphoma(DBL)before treatment and their clinical significance.Methods Baseline data of 98 patients diagnosed with diffuse large B-cell lymphoma(DLBCL)from January 2015 to December 2018 were collected.The relationship between RDW and STAT3 and the clinicopathological characteristics of DLBCL(Ann Arbor stage,Hans standard classification,lactate dehydrogenase and ECOG-PS)was analyzed.The relationship between RDW,STAT3 and prognosis of DLBCL was investigated.Results ROC curve results showed that the cut-off values of RDW and STAT3 were 14.55%and 23.85%,respectively.According to the cut-off values,DLBCL patients were divided into high and low RDW group and high and low STAT3 expression group.RDW and STAT3 were not related to gender,age or ECOG PS score(P>0.05),but were related to LDH level,Hans typing and Ann Arbor stage,and the difference was statistically significant(P<0.05).The overall survival of patients in the high RDW group and high STAT3 group was significantly lower than that in the low RDW group and low STAT3 expression group(P<0.05).Conclusion Red blood cell distribution width and STAT3 expression can be used as convenient indicators to evaluate the clinicopathological features and prognosis of patients with diffuse large B-cell lymphoma.